newsfilter
← Latest News
GlobeNewswire·

Adaptimmune Reports Second Quarter Financial Results and Business Update

- SPEARHEAD-1 data presented at ASCO with overall response rate of 39.3% in synovial sarcoma and MRCLS; on track to file BLA for afami-cel next year - - SURPASS trial data from 23 evaluable patients to be presented at ESMO - - ADP-A2AFP Phase 1 tri